Paul van der Leest et al. – Detection and Monitoring of Tumor-Derived Mutations in Circulating Tumor DNA Using the UltraSEEK Lung Panel on the MassARRAY System in Metastatic Non-Small Cell Lung Cancer Patients; International Journal of Molecular Sciences, 2023, 24, 13390; https://doi.org/10.3390/ijms241713390 (Link zur Publikation: https://www.mdpi.com/1422-0067/24/17/13390 )

Heidrich et al. – Liquid biopsy for monitoring of tumor dormancy and early detection of disease recurrence in solid tumors; Cancer Metastasis Rev (2023). https://doi.org/10.1007/s10555-022-10075-x (Link zur Publikation: https://link.springer.com/article/10.1007/s10555-022-10075-x )

Wankhede et al. – Circulating Tumor Cells as a Predictive Biomarker in Resectable Lung Cancer: A Systematic Review and Meta-Analysis; Cancers 2022, 14(24), 6112; https://doi.org/10.3390/cancers14246112 (Link zur Publikation: https://www.mdpi.com/2072-6694/14/24/6112 )

J. Pascual et. al. - ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group; Annals of Oncology, 2022, 33, 8, 750-768; https://doi.org/10.1016/j.annonc.2022.05.520 (Link zur Publikation: https://www.annalsofoncology.org/action/showPdf?pii=S0923-7534%2822%2901721-5

Liquid Biopsy: From Discovery to Clinical Application
Interesting new review by ELBS pioneers Dr. Catherine Alix-Panabieres and Prof. Dr. med. Klaus Pantel on bridging the gap between state-of-the-art research and the clinical application of liquid biopsies.
cancerdiscovery.aacrjournals.org/content/11/4/858